GSK Enters Lucrative Lupus Collaboration with Chinese Biotech Firm

In a significant move in the biopharmaceutical sector, GlaxoSmithKline plc (GSK) has struck a potential deal worth as much as $850 million with a Chinese biotech company to collaborate on treatments for lupus, an autoimmune disease affecting millions worldwide. This partnership is set to leverage the strengths of both companies, aiming to accelerate the development of new therapeutic options for patients.

Continue reading